Skip to main content
Equibles
TVGN logo

TVGN · Tevogen Inc. · Documents

Track TVGN — free

Use TVGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TVGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.72 -0.20 (-3.38%) At close · Nov 4
Rebalance outlook locked
Market Cap
$37.25M
Shares
6.51M
Volume · Nov 4 2606 Avg daily vol (3M) 8184

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $26.28M 10-K filed Mar 31, 2026 Quarterly report FY2026 Q2 Net loss $5.76M 10-Q filed Aug 14, 2026 Latest results Financial results 8-K filed Apr 26, 2024
2026
Nov 3
Current report 8-K Events of Oct 27
Debt repaid alongside performance-conditioned CEO stock award

Tevogen Inc. extended its facility to May 31, 2029 and repaid $7.4 million plus $177,880 interest in 1,000,000 Principal Shares and 23,733 Interest Shares. Ryan Saadi received 50,000,000 restricted shares vesting at $1.0 billion revenue by December 31, 2031.

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Director or officer change, or executive pay Read from the first part of this long document
6 source passages
The Amendment, among other things: (i) extends the period during which the Company can request borrowings under the Facility from May 31, 2027 to May 31, 2029; As of the First Amendment Effective Date, the outstanding principal balance of the loans borrowed under the Original Agreement was $7.4 million. Following the Amendment, the Company elected to repay the entire outstanding principal balance, together with $177,880 of accrued and unpaid interest, in shares of Common Stock at the Share Payment Price. On November 2, 2026, the Company issued to the Lender 1,000,000 Principal Shares and 23,733 Interest Shares in payment thereof thereby eliminating all outstanding liabilities under the Agreement. On November 2, 2026 (the “Grant Date”), Tevogen Inc. (the “Company”) granted Ryan Saadi, Chief Executive Officer and Chairperson of the Company’s Board of Directors (the “Board”), a restricted stock award (the “RSA”) under the Tevogen Inc. 2024 Omnibus Incentive Plan (the “Plan”), covering 50,000,000 shares (“Restricted Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”). The Restricted Shares will vest only upon the Board’s certification of the Company’s achievement of $1.0 billion in aggregate revenue by December 31, 2031 (the “Revenue Threshold”) and satisfaction of the other applicable vesting conditions. Open the document at this passage
Sep 30
Current report 8-K Events of Sep 29
Other events

Tevogen Inc. regained Nasdaq Global Market continued-listing compliance after receiving written notice on September 29, 2026 that it met the $50 million minimum market value requirement; both previously disclosed Nasdaq compliance matters are now closed.

Sep 10
Current report 8-K Events of Sep 9
Other events AI summary on its way
Mar 31
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $26.28M Diluted EPS -$8.08
Mar 25
Current report 8-K Events of Mar 20
Other events AI summary on its way
2025
2024
Showing 1–50 of 114 documents
Key facts CIK 1860871 CUSIP 88165K200 13F (30d) 10 filings 10 filers Visit website Investor relations